(NASDAQ: ARVN) Arvinas's forecast annual revenue growth rate of -39.62% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 101.11%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.31%.
Arvinas's revenue in 2025 is $312,300,000.On average, 20 Wall Street analysts forecast ARVN's revenue for 2025 to be $16,671,984,479, with the lowest ARVN revenue forecast at $13,532,058,746, and the highest ARVN revenue forecast at $20,635,265,662. On average, 20 Wall Street analysts forecast ARVN's revenue for 2026 to be $6,466,101,920, with the lowest ARVN revenue forecast at $1,039,791,320, and the highest ARVN revenue forecast at $11,585,420,395.
In 2027, ARVN is forecast to generate $6,590,697,050 in revenue, with the lowest revenue forecast at $2,061,920,959 and the highest revenue forecast at $15,706,051,098.